• KOL
    • Vertebral Fractures
    • Lisa Palermo
    • Lisa Palermo: Influence Statistics

      Lisa Palermo

      Lisa Palermo

      Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA. | University of California, San Francisco San Francisco CA USA | ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Lisa Palermo:Expert Impact

      Concepts for whichLisa Palermohas direct influence:Vertebral fractures,Vertebral fracture,Fracture intervention trial,Parathyroid hormone,5 years,Hip fracture,Bone density,Frax score.

      Lisa Palermo:KOL impact

      Concepts related to the work of other authors for whichfor which Lisa Palermo has influence:Vertebral fractures,Postmenopausal women,Hip fracture,Bone mineral density,Femoral neck,Parathyroid hormone,Lumbar spine.

      KOL Resume for Lisa Palermo

      Year
      2017

      Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA.

      2015

      University of California, San Francisco San Francisco CA USA

      2014

      University of California, San Francisco, San Francisco, CA, USA

      2013

      University of California, 185 Berry St., Suite 5700, 94107, San Francisco, CA, USA

      2012

      Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA

      2011

      Departments of Medicine (Dr Bauer) and Epidemiology and Biostatistics (Drs Schwartz, Vittinghoff, Bauer, and Black and Ms Palermo), University of California, San Francisco

      2010

      From the University of California at San Francisco, San Francisco (D.M.B., M.P.K., H.K.G., L.P., D.C.B.)

      Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA

      2009

      Department of Epidemiology and Biostatistics (D.M.B., L.P.), University of California at San Francisco, San Francisco, California 94107

      Division of Neonatology, University of California, San Francisco, California

      UC San Francisco and SF Coordinating Center, San Francisco, CA, USA

      2008

      San Francisco Coordinating Center (D.M.B., L.P.), University of California, San Francisco (UCSF), San Francisco, California 94107

      2007

      San Francisco Coordinating Center; Departments of Epidemiology and Biostatistics and Medicine, University of California, San Francisco, and California Pacific Medical Research Institute, San Francisco; Department of Medicine, VA Medical Center, Minneapolis, Minnesota; Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Medicine, University of Miami, Miami, Florida; School of Medicine, Wake Forest University, Winston-Salem, North Carolina; Department of Preventive Medicine, University of Tennessee, Memphis; College of Medicine, University of Iowa, Iowa city; and Merck Research Laboratories, Rahway, New Jersey

      2006

      From the *Division of Geriatrics, Department of Medicine, The David Geffen School of Medicine at University of California, Los Angeles, Los Angeles; †Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco; ‡Department of Radiology, University of California, San Francisco, San Francisco; and §California Pacific Medical Center, San Francisco, CA.

      Department of Epidemiology (L.P., D.M.B.), University of California, San Francisco, California 94107

      UCSF Prevention Sciences Group, University of California‐San Francisco, San Francisco, CA, USA;

      2005

      From the Departments of Epidemiology and Biostatistics (D.M.B., L.P., T.H.) and Radiology (T.F.L.), University of California, San Francisco

      2004

      San Francisco Coordinating Center and Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA

      2003

      Division of Epidemiology, Department of Epidemiology and Biostatistics, 74 New Montgomery St., Suite 600, University of California at San Francisco, San Francisco, CA 94105, USA

      From the Departments of Epidemiology and Biostatistics (D.M.B., L.P.) and Radiology (T.F.L.), University of California, San Francisco, San Francisco

      2002

      Department of Epidemiology and Biostatistics, University of California, San Francisco;, USA

      2001

      University of California, San Francisco, CA

      2000

      Univeraity of California, San Francisco. A complete list of the members of the Fracture Intervention Trial Research Group appears at the end of this article.

      1999

      University of California Prevention Sciences Group, San Francisco, CA, USA

      1998

      University of California at San Francisco, 74 New Montgomery Street, Suite 600, San Francisco, CA 94105, USA

      1996

      University of California at San Francisco, California

      1995

      Department of Epidemiology, Prevention Sciences Group, University of California, San Francisco, U.S.A

      1994

      Prevention Sciences Group, University of California San Francisco Medical Center, San Francisco, California, USA

      1993

      University of California, San Francisco, San Francisco, California 94143, U.S.A.

      1991

      Division of Clinical Epidemiology, Department of Epidemiology and Biostatistics, University of California, San Francisco

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Lisa Palermo is among the top experts in the world.
      Concept World rank
      mexican population year #1
      radiographic vertebral fractures #1
      4 alendronate #1
      ascertained vertebral #1
      steady age increments #1
      686 95 population #1
      radiographically ascertained #1
      age frax #1
      bmd prevalent #1
      year age distribution #1
      treatment alendronate #1
      vertebral fractures mexican #1
      digital xray #2
      trial higher costs #2
      bmd dxrbmd #2
      deformities incident #2
      bmd year #2
      spine fractures followup #2
      7782 women #2
      alendronate bmd benefit #2
      1–84 #2
      effects respiratory outcomes #2
      bmd lose #2
      persistent determined #2
      vertebral fracture reduction #2
      risk spine fractures #2
      alendronate lose #2
      ibandronate concurrent #2
      respiratory resource #2
      respiratory support control #2
      combination parathyroid #2
      ino therapy bpd #2
      alendronate reduction #2
      postmenopausal predictive #2
      lose bmd #2
      radiographs vertebral #2
      lost ” #2
      women vertebral #2
      bmd 4 #2
      95 vertebral fractures #2
      combination parathyroid hormone #2
      surfactant rb #2
      pronosco posure #2
      Sign-in to see all concepts, it's free!

      Prominent publications by Lisa Palermo

      KOL-Index: 23564

      CONTEXT: Alendronate sodium reduces fracture risk in postmenopausal women who have vertebral fractures, but its effects on fracture risk have not been studied for women without vertebral fractures.

      OBJECTIVE: To test the hypothesis that 4 years of alendronate would decrease the risk of clinical and vertebral fractures in women who have low bone mineral density (BMD) but no vertebral fractures.

      DESIGN: Randomized, blinded, placebo-controlled trial.

      SETTING: Eleven community-based clinical ...

      Known for Vertebral Fractures | Alendronate Risk | Fracture Intervention Trial | Photon Aged Aged | Low Bone
      KOL-Index: 19924

      CONTEXT: Type 2 diabetes mellitus (DM) is associated with higher bone mineral density (BMD) and paradoxically with increased fracture risk. It is not known if low BMD, central to fracture prediction in older adults, identifies fracture risk in patients with DM.

      OBJECTIVE: To determine if femoral neck BMD T score and the World Health Organization Fracture Risk Algorithm (FRAX) score are associated with hip and nonspine fracture risk in older adults with type 2 DM.

      DESIGN, SETTING, AND ...

      Known for Frax Score | Dm Hip Fracture | Type 2 | Neck Bmd | Risk Older
      KOL-Index: 18427

      CONTEXT: The optimal duration of treatment of women with postmenopausal osteoporosis is uncertain.

      OBJECTIVE: To compare the effects of discontinuing alendronate treatment after 5 years vs continuing for 10 years.

      DESIGN AND SETTING: Randomized, double-blind trial conducted at 10 US clinical centers that participated in the Fracture Intervention Trial (FIT).

      PARTICIPANTS: One thousand ninety-nine postmenopausal women who had been randomized to alendronate in FIT, with a mean of 5 years ...

      Known for 5 Years | Fracture Intervention Trial | Risk Women | Continuing Alendronate | Biochemical Markers
      KOL-Index: 17137

      The validity of the WHO 10-yr probability of major osteoporotic fracture model (FRAX) for prediction of vertebral fracture has not been tested. We analyzed how well FRAX for major osteoporotic fractures, with and without femoral neck BMD (FN BMD), predicted the risk of vertebral fracture. We also compared the predictive validity of FRAX, FN BMD, and prevalent vertebral fracture detected by radiographs at baseline alone or in combination to predict future vertebral fracture. We analyzed ...

      Known for Vertebral Fracture | Frax Bmd | Major Osteoporotic | Predicted Risk | Bone Density
      KOL-Index: 16227

      The assessment of radiographs for vertebral fractures is important in the clinical evaluation of patients with suspected osteoporosis, in the epidemiological evaluation of elderly populations, and in clinical trials of osteotrophic drugs. The purpose of this study is to compare visual semiquantitative (SQ) approaches and quantitative morphometric approaches for assessing prevalent and incident vertebral fractures in postmenopausal osteoporosis. We analyzed lateral thoracolumbar spine ...

      Known for Vertebral Fractures | Morphometric Assessment | Quantitative Morphometry | Prevalent Incident | Evaluation Studies
      KOL-Index: 16224

      The "PTH and Alendronate" or "PaTH" study compared the effects of PTH(1-84) and/or alendronate (ALN) in 238 postmenopausal, osteoporotic women. We performed finite element analysis on the QCT scans of 162 of these subjects to provide insight into femoral strength changes associated with these treatments and the relative roles of changes in the cortical and trabecular compartments on such strength changes. Patients were assigned to either PTH, ALN, or their combination (CMB) in year 1 and ...

      Known for Finite Element Analysis | Femoral Strength | Pth Aln | Cortical Trabecular | 1 Year
      KOL-Index: 16165

      OBJECTIVE: To describe progression over 8 years in a community-based sample of elderly women with radiographic findings of hip osteoarthritis (RHOA) with or without hip pain.

      METHODS: Baseline and followup anteroposterior pelvic radiographs were obtained at a mean +/- SD 8.3 +/- 0.4 years of followup in women age > or =65 years at the baseline examination of the Study of Osteoporotic Fractures. We evaluated progression in 936 hips of 745 women with one or more baseline findings of RHOA: ...

      Known for Radiographic Hip | 25 Mm | Baseline Followup | Elderly White Women | 8 Years
      KOL-Index: 15765

      Vertebral fractures in older women signal an increased risk of additional osteoporotic fractures. To identify risk factors for first vertebral fractures, we studied 5822 women > or =65 years of age who had no fracture on baseline radiographs of the spine. Several modifiable risk factors increased an older woman's risk of developing a first vertebral fracture, and women with multiple risk factors and low BMD had the highest risk. Risk factors and low BMD should be useful to help focus ...

      Known for Vertebral Fracture | Bmd Women | 65 Years | Baseline Radiographs | Factors Increased
      KOL-Index: 15755

      It is commonly believed that the response to treatment in patients on alendronate is proportional to the increase in bone mineral density (BMD), and that those who lose BMD during treatment might not respond to treatment. In the Fracture Intervention Trial 6,459 women were randomly assigned to treatment with alendronate or placebo; BMD was measured annually, and new spine fractures were assessed by lateral spine films, taken at baseline and end of follow-up. Among subjects who took at ...

      Known for Bmd Treatment | Bone Density | Fracture Intervention Trial | Placebo Women | Total Hip
      KOL-Index: 15438

      CONTEXT: Bone marrow fat (BMF) and bone mineral density (BMD) by dual x-ray energy absorptiometry (DXA) are negatively correlated. However, little is known about the association of BMF with fracture or with separate trabecular and cortical bone compartments.

      OBJECTIVE: Our objective was to assess the relationships between vertebral BMF, BMD by quantitative computed tomography, and fracture in older adults.

      DESIGN, SETTING, AND PARTICIPANTS: We conducted a cross-sectional study in the Age ...

      Known for Vertebral Bone | Bmf Bmd | Marrow Fat | Total Hip | Quantitative Computed Tomography
      KOL-Index: 15318

      CONTEXT: The principle of "regression to the mean" predicts that patients with unusual responses to treatment might represent outliers who are likely to have more typical responses if treatment is continued without change.

      OBJECTIVE: To test whether women who lose bone mineral density (BMD) during the first year of treatment for osteoporosis continue to lose BMD if the same treatment is continued beyond 1 year.

      DESIGN AND SETTING: Two randomized, double-blind, placebo-controlled trials ...

      Known for Bmd Treatment | Bone Densitometry | Osteoporosis Therapy | 2 Years | Alendronate Raloxifene
      KOL-Index: 15202

      BACKGROUND: Since the use of parathyroid hormone as a treatment for osteoporosis is limited to two years or less, the question of whether antiresorptive therapy should follow parathyroid hormone therapy is important. We previously reported results after the first year of this randomized trial comparing the use of full-length parathyroid hormone (1-84) alone, alendronate alone, or both combined. In the continuation of this trial, we asked whether antiresorptive therapy is required to ...

      Known for Parathyroid Hormone | Alendronate Therapy | Female Fractures | Bone Mineral Density | Year 1
      KOL-Index: 15137

      CONTEXT: Treatment of osteoporotic women with PTH increases biochemical markers of bone turnover, increases axial bone mineral density (BMD), and reduces fracture risk.

      OBJECTIVE: Our objective was to determine the relationship between levels of baseline turnover before PTH therapy and short-term changes in turnover during PTH therapy and subsequent changes in areal and volumetric BMD.

      DESIGN AND SETTING: We conducted a randomized, placebo-controlled trial at four academic ...

      Known for Postmenopausal Women | Bone Turnover | Parathyroid Hormone | Photon Aged Aged | Pth Therapy
      KOL-Index: 15118

      A bone fractures only when loaded beyond its strength. The purpose of this study was to determine the association of femoral strength, as estimated by finite element (FE) analysis of dual-energy X-ray absorptiometry (DXA) scans, with incident hip fracture in comparison to hip bone mineral density (BMD), Fracture Risk Assessment Tool (FRAX), and hip structure analysis (HSA) variables. This prospective case-cohort study included a random sample of 1941 women and 668 incident hip fracture ...

      Known for Femoral Strength | Dxa Scans | Osteoporotic Fractures | Incident Hip Fracture | Element Analysis

      Key People For Vertebral Fractures

      Top KOLs in the world
      #1
      Harry K Genant
      vertebral fractures rheumatoid arthritis postmenopausal women
      #2
      Michael C Nevitt
      knee pain osteoarthritis initiative cartilage loss
      #3
      Steven Ron Cummings
      hip fracture breast cancer older women
      #4
      Cyrus C Cooper
      hip fracture grip strength hertfordshire cohort study
      #5
      John A Kanis
      hip fracture postmenopausal women intervention thresholds
      #6
      Dennis M Black
      zoledronic acid hip fracture postmenopausal women

      Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA. | University of California, San Francisco San Francisco CA USA | Department of Epidemiology and Biostatistics, University of California San Franc

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.